Why is "CD137" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-05-28 22:17:12
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
CD137 entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-05-28 and was most recently seen on 2026-05-28.
Wikipedia Overview
CD137, a member of the tumor necrosis factor (TNF) receptor family, is a type 1 transmembrane protein, expressed on surfaces of leukocytes and non-immune cells. Its alternative names are tumor necrosis factor receptor superfamily member 9 (TNFRSF9), 4-1BB, and induced by lymphocyte activation (ILA). It is of interest to immunologists as a co-stimulatory immune checkpoint molecule, and as a potential target in cancer immunotherapy.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
MIF tautomerase inhibitor 4-IPP alleviates HFD-induced obesity by restoring CD137-mediated browning of white adipocytes in mice | Acta Pharmacologica Sinica - Nature
-
Ankyra Therapeutics Presents First Preclinical Data on ANK-203, a Novel CD137-Anchored Immunotherapy Candidate, in Oral Session at AACR IO - biospace.com
-
Preclinical Evaluation and Pilot Clinical Study of CD137 PET Radiotracer for Noninvasive Monitoring Early Responses of Immunotherapy - Journal of Nuclear Medicine
-
T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation - Nature
-
BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors - OncLive
-
Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy - Wiley Online Library
-
AP Biosciences charts course for safer CD137 bispecifics with its T-cube platform - drugdiscoverytrends.com
-
CD137L promotes immune surveillance in melanoma via HLTF regulation - Nature
-
Clinical & Translational Immunology | ASI Journal - Wiley Online Library
-
A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade - Nature
-
Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicity - Nature
-
CD137 (4-1BB) stimulation leads to metabolic and functional reprogramming of human monocytes/macrophages enhancing their tumoricidal activity - Nature
-
A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma - Nature
-
In vivo imaging with two-photon microscopy to assess the tumor-selective binding of an anti-CD137 switch antibody - Nature
-
CD137 ligand interacts with CD32a to trigger reverse CD137 ligand signaling - Nature
-
4-1BB immunotherapy: advances and hurdles - Nature
-
Polyclonal expansion of functional tumor-reactive lymphocytes infiltrating glioblastoma for personalized cell therapy - Nature
-
A mathematical model of combined CD8 T cell costimulation by 4-1BB (CD137) and OX40 (CD134) receptors - Nature
-
CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy - Nature
-
Combined congenic mapping and nuclease-based gene targeting for studying allele-specific effects of Tnfrsf9 within the Idd9.3 autoimmune diabetes locus - Nature
-
Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 expression - PLOS
-
Modulation of urelumab glycosylation separates immune stimulatory activity from organ toxicity - Frontiers
-
Keys to making immunotherapy work against pancreatic cancer found in tumor microenvironment - Johns Hopkins Medicine
-
Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity - Nature
-
Dual Activation‐Induced Marker Combinations Efficiently Identify and Discern Antigen‐Specific and Bystander‐Activated Human CD4+ T Cells - Wiley Online Library
-
Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapy - PNAS
-
Immuno-PET tracer shows promise in patients with liver cancer - AuntMinnie
-
An optimized flow cytometry protocol for simultaneous detection of T cell activation induced markers and intracellular cytokines: application to SARS-Cov-2 vaccinated individuals - medRxiv
-
Roche axes 4 Chugai solid tumor assets in early-phase clear-out - Fierce Biotech
-
CD137 ligand-mediated reverse signals increase cell viability and cytokine expression in murine myeloid cells: Involvement of mTOR/p70S6 kinase and Akt - Wiley Online Library
-
The Road Less Taken: Less Appreciated Pathways for Manipulating CD8+ T Cell Exhaustion - Frontiers
-
Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab - Nature
-
4-1BB: A promising target for cancer immunotherapy - Frontiers
-
Transcriptional and functional characterization of CD137L-dendritic cells identifies a novel dendritic cell phenotype - Nature
-
Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies - National Institutes of Health (NIH) | (.gov)
-
The Ways of Isolating Neoantigen-Specific T Cells - Frontiers
-
Designing antibodies to think before they bind - Drug Target Review
-
In vivo stimulation of CD137 broadens primary antiviral CD8 - Nature
-
Flow‐cytometric analysis of rare antigen‐specific T cells - Bacher - 2013 - Cytometry Part A - Wiley Online Library
-
Rapid TCR:Epitope Ranker (RAPTER): a primary human T cell reactivity screening assay pairing epitope and TCR at single cell resolution - Nature
-
Agonism of 4-1BB for immune therapy: a perspective on possibilities and complications - Frontiers
-
CD137L-DCs, Potent Immune-Stimulators—History, Characteristics, and Perspectives - Frontiers
-
Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival - Springer Nature Link
-
Antigen-specific expansion of human regulatory T cells as a major tolerance mechanism against mucosal fungi - Nature
-
Levels of soluble CD137 are enhanced in sera of leukemia and lymphoma patients and are strongly associated with chronic lymphocytic leukemia - Nature
-
Pancreatic cancer vaccine plus immunotherapy and antibody spark immune system response in pancreatic cancers - Medical Xpress
-
4-1BB signaling activates glucose and fatty acid metabolism to enhance CD8 - Nature
-
T cell priming that is required for curative intratumorally anchored anti-4-1BB immunotherapy is constrained by Tregs - Nature
-
Finding antitumor T cells in a patient's own cancer - Medical Xpress
-
4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity - Frontiers
-
Immunology & Cell Biology | ASI Journal - Wiley Online Library
-
Double-Barreled Antibodies - Genetic Engineering and Biotechnology News
-
Genmab ends lung cancer drug development - pharmaphorum.com
-
CD137+ Tumor Infiltrating Lymphocytes Correlate With OS in Ovarian Cancer, Study Finds - The American Journal of Managed Care
-
Selection of highly responsive T cell receptors by an analysis combining the expression of multiple markers - Wiley Online Library
-
Study uncovers new factor in the development of childhood lymphoma - News-Medical
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.